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Biomarker studies used with immunotherapeutic strate-
gies in the clinic have typically involved monitoring
immunologic changes within the systemic circulation;
however, recent data indicate that immunological
changes within tumor tissues will be more likely to pre-
dict clinical responses. To obtain such data we conducted
the first pre-surgical clinical trial with anti-CTLA-4 (ipili-
mumab) in a cohort of patients with localized bladder
cancer. We are also conducting the first combination
therapy pre-surgical trial with ipilimumab plus leuprolide
acetate in patients with localized prostate cancer. Immu-
nological data from these trials are obtained from both
tumor tissues and blood samples.
We found an increased frequency of CD4 and CD8
T cells expressing high levels of inducible costimulator
(ICOS) and decreased frequency of FOXP3-expressing
CD4 T cells within tumor tissues of treated patients.
The CD4+ICOShi population contained effector T cells
that produced IFN-g and recognized the cancer-testis
antigen NY-ESO-1 expressed on tumor cells. We there-
fore identified ICOS as marker of a subset of effector
T cells that is increased in frequency after anti-CTLA-4
therapy. ICOS+ T cells are being explored as both a
pharmacodynamic marker for treatment with anti-
CTLA-4 as well as a novel target to improve the efficacy
of anti-CTLA-4 therapy.
These observations led us to test the possibility that
engagement of ICOS could enhance the efficacy of anti-
CTLA-4 therapy. To this end we transduced mouse
B16F10 melanoma cells with a cDNA encoding ICOSL or
a control construct. B16-ICOSL+ cells (IVAX) and control
B16 cells were irradiated and used alone or in combination
with anti-CTLA-4 to treat mice bearing established
B16F10 tumors. We found that combination of the IVAX
with anti-CTLA-4 was markedly more effective than the
control vaccine plus anti-CTLA-4 or that of any single
treatment alone. The increase in therapeutic efficacy was
accompanied by a marked in increase in the density and
functionality of CD4 and CD8 T cells within the tumor.
These results suggest a novel strategy for manipulating
the immune system to enhance anti-tumor responses:
checkpoint blockade coupled with provision of agonist sig-
nals to enhance costimulation mediated by ICOS.
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